GLP‑1 dose schedules explained - titration, maintenance, and what to expect at each level

Introduction

Every GLP‑1 medication follows a structured titration schedule that gradually increases your dose over weeks or months, and understanding this timeline is key to setting realistic expectations about results and side effects. Starting low and going slow is not optional. It is how these medications are designed to work. Patients who try to skip dose levels or accelerate their titration face significantly higher rates of nausea, vomiting, and treatment discontinuation. This guide covers the complete dose schedules for the major GLP‑1 medications and what to expect at each level.

Why titration exists

The gradual dose increase serves specific physiological purposes:

• GI adaptation: GLP‑1 receptor agonists slow gastric emptying and alter gut motility. Starting at full dose would cause severe nausea and vomiting in most patients. The lower doses give your digestive system time to adjust.
• Receptor upregulation: Your body needs time to adapt to sustained GLP‑1 receptor stimulation. Gradual exposure allows receptor sensitivity to calibrate without overwhelming the system.
• Side effect management: Clinical trial data consistently shows that patients who follow the recommended titration schedule have lower dropout rates. Going too fast increases the risk of intolerable side effects that lead patients to stop treatment entirely.
• Individual response assessment: Each dose level reveals how your body responds. Some patients achieve their goals at moderate doses and never need the maximum, saving cost and reducing unnecessary side effect burden.

Semaglutide for weight loss (Wegovy)

Wegovy’s titration schedule spans 16 weeks before reaching the full maintenance dose:

• Weeks 1 to 4: 0.25 mg once weekly. This is a sub-therapeutic dose meant purely for GI adaptation. Expect minimal weight loss but noticeable appetite changes. Nausea affects roughly 20 percent of patients at this level.
• Weeks 5 to 8: 0.5 mg once weekly. Appetite suppression becomes more consistent. Most patients notice a clear difference in hunger and portion size. Weight loss of 2 to 4 percent from baseline is typical by the end of this phase.
• Weeks 9 to 12: 1 mg once weekly. This is where meaningful weight loss accelerates for most patients. Side effects that subsided at 0.5 mg may briefly return, then improve within one to two weeks.
• Weeks 13 to 16: 1.7 mg once weekly. A significant step up. Nausea recurrence is common for the first week at this dose. Appetite suppression is strong and consistent for most patients.
• Week 17 onward: 2.4 mg once weekly (maintenance dose). The full therapeutic dose. Maximum appetite suppression and weight loss effect. Most patients reach their weight loss nadir between weeks 60 and 68 at this dose.

Semaglutide for diabetes (Ozempic)

Ozempic uses a slightly different schedule with fewer steps:

• Weeks 1 to 4: 0.25 mg once weekly. Adaptation phase with minimal glycemic impact beyond the dose’s modest effect.
• Weeks 5 to 8: 0.5 mg once weekly. First therapeutic dose for glycemic control. Many patients see meaningful A1C improvement here.
• Week 9 onward: 1 mg once weekly. Standard maintenance dose for most patients. Some providers increase to 2 mg if glycemic targets are not met after adequate time at 1 mg.

The 2 mg dose was added later and produces additional weight loss beyond what 1 mg achieves, though it is primarily indicated for glycemic control.

Tirzepatide for weight loss (Zepbound)

Zepbound has more dose levels and a longer minimum titration period of 20 weeks:

• Weeks 1 to 4: 2.5 mg once weekly. The adaptation dose. Because tirzepatide activates both GIP and GLP‑1 receptors, the GI adjustment period can feel different from semaglutide. Some patients report less nausea but more appetite suppression at this starting dose.
• Weeks 5 to 8: 5 mg once weekly. First meaningful therapeutic dose. Weight loss typically becomes consistent and measurable. The dual-receptor mechanism begins to show its distinct effect profile.
• Weeks 9 to 12: 7.5 mg once weekly. An intermediate step that many patients tolerate well. Appetite suppression deepens and food noise continues to decrease.
• Weeks 13 to 16: 10 mg once weekly. A significant dose level where many patients find their effective maintenance range. Some providers pause titration here if results are satisfactory.
• Weeks 17 to 20: 12.5 mg once weekly. The penultimate dose. Patients who need maximum weight loss continue through this level.
• Week 21 onward: 15 mg once weekly (maximum dose). The highest available dose. In SURMOUNT-1, patients on 15 mg achieved average weight loss of 22.5 percent at 72 weeks.

Tirzepatide for diabetes (Mounjaro)

Mounjaro follows the same dose steps as Zepbound (2.5, 5, 7.5, 10, 12.5, 15 mg) with four-week intervals at each level. The primary difference is the clinical goal: A1C reduction and glycemic stability rather than maximum weight loss. Many diabetes patients find their effective dose at 5 or 10 mg without needing the higher levels.

What happens at each dose increase

Regardless of which medication you take, dose increases follow a predictable pattern:

• Days 1 to 3: Side effects from the higher dose may appear, particularly nausea, reduced appetite, and mild fatigue. These reflect the stronger GLP‑1 receptor activation your body has not yet adapted to.
• Days 4 to 7: Symptoms typically peak in this window. Eating smaller meals, staying hydrated, and avoiding high-fat foods helps manage GI discomfort.
• Week 2: Most patients report significant improvement. The body begins adapting to the new stimulation level. Appetite suppression at the higher dose becomes the new normal.
• Weeks 3 to 4: Side effects are usually at baseline or below. Weight loss at the new dose level becomes consistent. This is when you and your provider assess whether to continue increasing.

When providers slow down or pause titration

Not every patient follows the textbook schedule. Your prescriber may adjust the timeline if:

• Side effects are severe: Staying at a lower dose for an extra four weeks (or longer) until symptoms resolve is common and appropriate.
• Results are adequate: If you are losing weight steadily at 1 mg semaglutide or 10 mg tirzepatide, increasing further may not be necessary.
• Supply issues: Medication shortages may force patients to remain at available dose levels rather than advancing on schedule.
• Cost management: Higher doses cost the same per pen but last fewer weeks if prescribed off-label at adjusted intervals. Some patients stay at moderate doses to manage expenses.

Track every dose with Shotsy

Shotsy tracks your exact dose with each injection and lets you set reminders timed to your specific titration schedule. The Results tab shows your dosage history alongside weight trends, making it easy to see how each dose increase correlates with your progress. When it is time to discuss your next step with your provider, your complete dose history is already organized.

Conclusion

GLP‑1 dose titration is a deliberate process designed to maximize results while minimizing the side effects that cause patients to quit. Whether you are on semaglutide or tirzepatide, expect side effects to peak briefly after each dose increase and then improve within one to two weeks. Not everyone needs the maximum dose, and the right maintenance level is the one that produces adequate results with tolerable side effects. Track each dose level carefully so you have clear data on what works for your body.